EBITDA Margin % is calculated as EBITDA divided by its Revenue. Rockwell Medical's EBITDA for the
three
months ended in Mar. 2026 was €-1.14 Mil. Rockwell Medical's Revenue for the
three
months ended in Mar. 2026 was €15.00 Mil. Therefore, Rockwell Medical's EBITDA margin for the quarter that ended in Mar. 2026 was -7.63%.
Rockwell Medical (FRA:RWMA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Rockwell Medical EBITDA Margin % Related Terms
Rockwell Medical EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Rockwell Medical's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RWMA vs MRMD, CPHI, HYEX: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rockwell Medical EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Rockwell Medical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rockwell Medical (FRA:RWMA) has a EBITDA Margin % of -7.63% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Rockwell Medical and its competitors. According to the industry distribution chart, Rockwell Medical ranks #752 out of 955 companies in the Drug Manufacturers industry, placing it in the top 78.7%.
Is Rockwell Medical's EBITDA Margin % too high?
Rockwell Medical's current EBITDA Margin % is -7.63%. Based on the distribution chart, Rockwell Medical ranks #752 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Rockwell Medical has a GF Score™ of 30/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rockwell Medical's EBITDA Margin % compare to MRMD and CPHI?
According to the Drug Manufacturers industry distribution chart, Rockwell Medical ranks #752 out of 955 companies for EBITDA Margin %. This places Rockwell Medical in the lower half of its industry. The industry median EBITDA Margin % is 12.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Rockwell Medical and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rockwell Medical's current EBITDA Margin % is -7.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rockwell Medical stock overvalued right now?
Based on GuruFocus' analysis, Rockwell Medical (FRA:RWMA) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.75, compared to a current price of €0.59 — trading 22% below its estimated fair value. The current EBITDA Margin % is -7.63%. Rockwell Medical's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Rockwell Medical (FRA:RWMA), the current EBITDA Margin % is -7.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rockwell Medical (FRA:RWMA) Overvalued in 2026?
Based on GuruFocus' analysis, Rockwell Medical stock appears to be undervalued.
The current stock price of €0.59 is trading 22% below its estimated GF Value™ of €0.75.
GuruFocus considers Rockwell Medical to be Modestly Undervalued.
Key valuation signals for FRA:RWMA:
EBITDA Margin %: -7.63%
GF Value™: €0.75 vs. price of €0.59 (22% below fair value)
No single metric tells the full story. See the FRA:RWMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
30GF Score
Get the complete analysis for FRA:RWMA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RWMA has been successfully added to your 
